Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SEP-4199 CR 12-month open-label extension in bipolar I depression
2021-002108-11Phase 3Terminated
- Sponsor
- Sunovion
- Start
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of SEP-4199 in bipolar I disorder, sponsored by Sunovion. Primary endpoint: Long-term safety and tolerability of SEP-4199 CR. Started Dec 2021; status: terminated.
02
Drugs
SEP-4199
03
Conditions
bipolar I disorder
Beyond the preview
Go deeper on 2021-002108-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002108-11.